Skip to main content

Table 2 Clinical data in validation cohort

From: Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy

 

Mean/count

std/%

 Age

55.40

7.99

 Follow up (month)

10.60

3.93

Outcomes

  

 Disease progression

8

53.33%

 Stable disease

7

46.67%

RCB score

  

 II

8

53.33%

 III

7

46.67%

Grade before NATI

  

 2

7

46.67%

 3

8

53.33%

Clinical stage before NATI

  

 2

8

53.33%

 3

7

46.67%

Tumor stage before NATI

  

 1

1

6.67%

 2

6

40.00%

 3

5

33.33%

 4

3

20.00%

Node stage before NATI

  

 1

7

46.67%

 2

5

33.33%

 3

3

20.00%

ICI types

  

 PD_L1 blockers

5

33.33%

 PD1 blockers

10

66.67%

  1. RCB_score, residual cancer burden score. ICI types, immune checkpoint inhibitor types
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us